Storm Therapeutics
@storm_tx
Followers
993
Following
228
Statuses
263
STORM Therapeutics is a biotech company discovering and developing novel small molecule therapies for RNA modification enzymes for oncology and other diseases
England, United Kingdom
Joined June 2016
Look out for the #STORM team at London Life Sciences Week! Our CEO, Jerry McMahon, will attend the upcoming @Jefferies London Healthcare Conference from 19-21 November alongside our CBO, Marguerite Hutchinson.
0
0
2
Check out the latest insights from our CEO, Jerry McMahon, featured in an article by International Clinical Trials discussing the current field of Alzheimer’s disease, drugs, biomarkers, and the future of treatment options for #neurogenerativediseases:
0
1
2
Visit our poster presentation at #SITC2024! 📝 Title: Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies 📅 Date: Saturday 9 November 📌 Abstract number: 676
0
0
2
STORM is in Barcelona for the EORTC-NCI-AACR (#ENA) Symposium! Poster details below 👇 📢 Session Title: New therapies in immuno oncology 📅 Session Date and Time: 25 October, 09:00 - 15:00 CEST 🏢 Location: Exhibition Hall 📌 Catalog Number: 451 🗞️ Presentation Number: PB439
0
0
1
Thanks to @Cambridge_Uni for spotlighting us as one of '10 Cambridge spinouts changing the story of cancer'! Check out STORM in the article 👇 and discover how we are pioneering cellular reprogramming through RNA modifications to treat disease🧬#lifesciences #biotech #cancer
💡A brilliant idea for helping cancer patients is just that – an idea – until it is put into practice. Here's how 10 companies spun out of research at Cambridge are doing it: #ChangingTheStoryOfCancer
0
0
6
Our CEO, Jerry McMahon, provides insight into the potential of STORM's lead product STC-15 "across multiple therapeutic areas" in @DDWJournal's article which delves into the new mechanisms of action, receptors and modalities in cancer immunotherapy, here:
0
1
5
#STORM's Senior Vice President Therapeutics, Matthew Fyfe, is chairing a session at the International Symposium on Medicinal Chemistry! 📢 Title: Session 4 'Chemical Biology': Targeting RNA and RNA-Regulatory Proteins 🕐 Date & Time: 2nd September, 13:45 CEST 📍 Rome, Italy
0
0
3
Great to see STORM's CEO, Jerry McMahon, featured in @Citeline's discussion on advancements in #oncology and the use of technology in the evolving landscape of drug development. 💡 An insightful discussion amongst experts from #ASCO2024! Read here:
Citeline and ICON Biotech collaborated with industry specialists to uncover how emerging technologies and strategic innovations are reshaping oncology development. Read the full report for free here:
0
2
7
Great to see #STORMTherapeutics featured in @Labiotech_eu's summary of 'Six epigenetics companies making strides in 2024.' Read about our interim Phase I clinical data on lead candidate #STC15, targeting solid tumors, here
0
1
4
#STORM is featured in @MedicalTechMag 'ASCO 2024 unveils practice - changing research in oncology' article! CEO, Jerry McMahon discusses the advances and current therapies presented at ASCO 2024. Read the full article here:
0
1
7
Thank you to @Drughuntersite for following our story. This piece offers an excellent update on #METTL3, sharing the exciting journey of #STC15 and the progression of our lead asset. We’re eager to continue and share our progress with you all! #ASCO2024 #RNA #drugdevelopment
STC15 is Storm Therapeutics' first-to-clinic METTL3 inhibitor, which progressed from HTS hit to clinical development in less than three years. Read about STC15’s discovery and development story here.
0
1
5
STORM is presenting at #ISMB2024, the world's largest conference focused on #bioinformatics and #computationalbiology! 📢 Presentation details: D-326: R toolkit for biomarker discovery, Track: TransMed 📅 Date, time & location: 16th July, 12:20-14:20 EDT - Montreal, Canada
0
0
3
#STORM's Senior Vice President Therapeutics, Matthew Fyfe, is joining a panel at #ONHelix2024! 4th July at 15:30 BST 'Translational Research in a Global Village' panelists will reflect on what's driving the UK life science sector's growth as a global bio-innovation location.
0
0
5
#STORM's Vice President Medicinal Chemistry, Beth Thomas, is presenting at the @SocMedRes' 'Modulating RNA with oligonucleotides or small molecules' conference! The conference will explore novel approaches and modalities in the field. Presentation: 21st June from 13.50 - 14.30!
0
0
5